Homburger advised ADC Therapeutics SA on its USD 60 m private placement of common shares and pre-funded warrants

On October 13, 2025, ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company headquartered in Switzerland, announced a USD 60 m private investment in public equity (“PIPE”) financing. In the PIPE, 11.3 m common shares and pre-funded warrants to purchase 3.8 m common shares were sold. The PIPE is led by TCGX and includes participation from Redmile Group and other existing investors.

The Homburger team was led by Daniel Häusermann (Corporate / M&A, Capital Markets) and included Bianca Nedwed (Corporate / M&A, Capital Markets) as well as Stefan Oesterhelt (Tax).